Patrick Mazi

Dr. Patrick Mazi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PMPatrick Mazi
Patrick Mazi
JSJohn M Sahrmann
John M Sahrmann
MOMargaret A Olsen
Margaret A Olsen
ACAriella Coler-Reilly
Ariella Coler-Reilly
ARAdriana M Rauseo
Adriana M Rauseo
ASAndrej Spec
Andrej Spec
The dimorphic mycoses (DMs) of the United States—Histoplasma, Coccidioides, and Blastomyces—commonly known as endemic mycoses of North America (in addition to Paracoccidioides) are increasingly being diagnosed outside their historical areas of endemicity. Despite this trend, the maps outlining their geographic distributions have not been updated in more than half a century using a large, nationwide database containing individual-patient–level data. This was a retrospective analysis of >45 million Medicare fee-for-service beneficiaries from 1 January 2007 through 31 December 2016. Diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were defined by International Classification of Diseases, Ninth/10th Revision, codes. The primary outcome was the incidence of histoplasmosis, coccidioidomycosis, and blastomycosis for each US county. Clinically meaningful thresholds for incidence were defined as 100 cases/100 000 person-years for histoplasmosis and coccidioidomycosis and 50 cases/100 000 person-years for blastomycosis. There were 79 749 histoplasmosis, 37 726 coccidioidomycosis, and 6109 blastomycosis diagnoses in unique persons from 2007–2016 across 3143 US counties. Considering all US states plus Washington, DC, 94% (48/51) had ≥1 county above the clinically relevant threshold for histoplasmosis, 69% (35/51) for coccidioidomycosis, and 78% (40/51) for blastomycosis. Persons with histoplasmosis, coccidioidomycosis, and blastomycosis are diagnosed in significant numbers outside their historical geographic distributions established >50 years ago. Clinicians should consider DM diagnoses based on compatible clinical syndromes with less emphasis placed on patients' geographic exposure. Increased clinical suspicion leading to a subsequent increase in DM diagnostic testing would likely result in fewer missed diagnoses, fewer diagnostic delays, and improved patient outcomes.

5 January 2022 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PMPatrick Mazi
Patrick Mazi
MOMargaret A Olsen
Margaret A Olsen
DSDustin Stwalley
Dustin Stwalley
ARAdriana M Rauseo
Adriana M Rauseo
CAChapelle Ayres
Chapelle Ayres
ASAndrej Spec
Andrej Spec
This study quantifies the mortality attributable to Candida bloodstream infections (BSI) in the modern era of echinocandins. We conducted a retrospective cohort study of adult patients admitted to Barnes Jewish Hospital, a 1368-bed tertiary care academic hospital, in Saint Louis, Missouri, from 1 February 2012 to 30 April 2019. We identified 626 adult patients with Candida BSI that were frequency-matched with 6269 control patients that had similar Candida BSI risk-factors. The 90-day all-cause mortality attributable to Candida BSI was calculated using three methods—propensity score matching, matching by inverse weighting of propensity score, and stratified analysis by quintile. The 90-day crude mortality was 42.4% (269 patients) for Candida BSI cases and 17.1% (1083 patients) for frequency-matched controls. Following propensity score-matching, the attributable risk difference for 90-day mortality was 28.4% with hazard ratio (HR) of 2.12 (95% confidence interval [CI], 1.98–2.25, P < .001). In the stratified analysis, the risk for mortality at 90 days was highest in patients in the lowest risk quintile to develop Candida BSI (hazard ratio [HR] 3.13 (95% CI, 2.33–4.19). Patients in this lowest risk quintile accounted for 81(61%) of the 130 untreated patients with Candida BSI. Sixty-nine percent of untreated patients (57/83) died versus 35% of (49/127) of treated patients (P < .001). Patients with Candida BSI continue to experience high mortality. Mortality attributable to Candida BSI was more pronounced in patients at lowest risk to develop Candida BSI. A higher proportion of these low-risk patients went untreated, experienced higher mortality, and should be the target of aggressive interventions to ensure timely, effective treatment.

8 May 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JCJoseph Cherabie
Joseph Cherabie
PMPatrick Mazi
Patrick Mazi
ARAdriana M. Rauseo
Adriana M. Rauseo
CAChapelle Ayres
Chapelle Ayres
LLLindsey Larson
Lindsey Larson
ASAndrej Spec
Andrej Spec
Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however, no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8% early mortality and 22.2% late mortality. There was no statistically significant difference in survival based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance with 38% of survivors having private insurance versus only 8% having private insurance in the late mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a contribution from social determinants of health, such as private insurance. Larger studies are needed to elucidate the role of these factors in the mortality of PWH.

29 September 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
RGReid Goodman
Reid Goodman
ARAdriana M Rauseo
Adriana M Rauseo
SWSamuel L Windham
Samuel L Windham
JZJulio Cesar Zuniga-Moya
Julio Cesar Zuniga-Moya
WPWilliam G Powderly
William G Powderly
PMPatrick Mazi
Patrick Mazi
Background: The dimorphic mycoses (DMs) histoplasmosis, blastomycosis, and coccidioidomycosis are classically thought to be geographically restricted to specific regions of the United States. The current scientific consensus is that these geographic boundaries are expanding, but the extent of this expansion remains uncertain. Methods: This study is a retrospective analysis of >21 million (annually) commercially insured individuals within the United States during 2007–2016. Diagnosis of histoplasmosis, coccidioidomycosis, and blastomycosis were identified using International Classification of Diseases, Ninth/Tenth Revision codes within the Merative MarketScan database. Results: There were 37 513 histoplasmosis, 14 987 coccidioidomycosis, and 2207 blastomycosis diagnoses during 2007–2016 within 387 Metropolitan Statistical Areas. DMs were consistently diagnosed outside their historical hyperendemic regions. Conclusions: New diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were routinely made outside their historically defined regions of endemicity. While exposure to hyperendemic regions remains a risk factor for developing a DM infection, clinicians should consider testing any patient presenting with a compatible clinical syndrome, regardless of their geographic history. Increased suspicion of DM infection will lead to fewer missed or delayed diagnoses, thereby improving patient outcomes.

5 August 2025 in Journal of Infection
Verified
Journal Article
Open access
JZJulio Cesar Zuniga-Moya
Julio Cesar Zuniga-Moya
BPBenjamin Papadopoulos
Benjamin Papadopoulos
AAAndrew Atkinson
Andrew Atkinson
PMPatrick Mazi
Patrick Mazi
ARAdriana M. Rauseo
Adriana M. Rauseo
ASAndrej Spec
Andrej Spec
Invasive mold infections-invasive aspergillosis and mucormycosis-have mortality rates as high as 90% in certain patient populations. Some clinical factors, such as prolonged neutropenia, are well-studied and are closely associated with increased mortality. However, the incidence of invasive aspergillosis and mucormycosis across geographic locations and its impact on mortality remains understudied. Geographic distribution and incidence rates of invasive aspergillosis and mucormycosis were mapped using 2008-2015 Medicare fee-for-service data. The association between the incidence of these fungal infections and 90-day mortality was investigated using adjusted generalized additive modeling. 53,321 patients were diagnosed with invasive aspergillosis, and 2655 had a diagnosis of mucormycosis. The western region of the United States reported the highest incidence rates (aspergillosis: 25.69 cases per 100,000 person-years; mucormycosis: 1.34 cases per 100,000 person-years). For every increase of 5 cases per 100,000 person-years in the incidence of IA, there was a 3.4% reduction in 90-day mortality (RR: 0.966; 95% CI: 0.961-0.972; p<0.0001) INTERPRETATION: Invasive aspergillosis and mucormycosis are widely distributed in the United States, with certain regions experiencing significantly higher incidences. For invasive aspergillosis, each increase of 5 cases per 100,000 claimant years was associated with a modest yet statistically significant 3.4% reduction in 90-day mortality. Conversely, the rise in incidence did not significantly affect mortality rates for mucormycosis.

26 April 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RPRobert Purdie
Robert Purdie
LTLisa A Tushla
Lisa A Tushla
JFJonathan Ferretti
Jonathan Ferretti
GCGonzalo (Kiko) Castro
Gonzalo (Kiko) Castro
RWRicky Watson
Ricky Watson
ASAndrej Spec
Andrej Spec
Background: Recently, increasing focus on patient input into research and healthcare improvements has fostered expanded patient-centered advocacy efforts. This first pan-fungal disease summit, part of the MYCology Advocacy, Research, & Education effort, brought together patients, caregivers, and mycology experts to better document patient experiences with invasive fungal disease (IFD) and establish priorities for mycology education, advocacy, and research. Methods: Patients who had suffered from IFD, their caregivers, clinicians, industry representatives, government officials, and patient advocacy professionals were invited. Patients and caregivers shared their stories and struggles with IFD. Breakout sessions separated mycology experts from patients and caregivers for further discussions to identify commonalities and perceived gaps and to formulate recommendations. The 2 groups then reconvened to develop consensus recommendations. Results: IFD patients and their caregivers shared experiences reflecting the typically lengthy prediagnosis, acute treatment, long-term treatment, and posttreatment recovery stages of IFD. They reported substantial physical, psychological, and financial burdens associated with the IFD experience, particularly related to delayed diagnoses. They reaffirmed a need for coordinated patient-centered education, peer support, and advocacy to document the burden of serious fungal infections. Mycology experts discussed strategies to address gaps in the mycology field, such as insufficient training, inadequate workforce support, and a need to partner more with patient groups. Conclusions: A summit involving patients with IFD, family caregivers, and mycology experts identified a substantial nonclinical burden of disease associated with IFD. Patients and mycology experts prioritized several goals for education, advocacy, and research to raise awareness of IFD and improve outcomes.